Cardiff Oncology, Inc. Q2 FY2024 earnings call

• Discussed lead program in RAS-mutated metastatic colorectal cancer (mCRC) with ongoing CRDF-004 trial, active in 33 sites, planning to enroll 90 patients randomized to onvansertib doses plus standard care, expecting initial data readout later this year.
• Update on pancreatic cancer program shifting to investigator-initiated trial combining onvansertib with NALIRIFOX due to NALIRIFOX being approved as first-line standard for metastatic PDAC.
• Preclinical data on onvansertib's activity in other cancer indications, including ovarian cancer resistant to PARP inhibitors, showing synergy with olaparib in vitro and in vivo.
• Financial position disclosed in Form 10-Q, with cash and short-term investments at $60.3M as of June 30, 2024, and cash used in operating activities $9.2M in Q2 2024.

No detailed product segment financial performance with revenue contribution % provided in the transcript.

• Cash runway expected through end of third quarter of 2025 based on current cash forecast.
• CRDF-004 trial on track for initial data readout later this year, including objective response rate data for approximately half of enrolled patients.

Forward-looking statements involve significant risks and uncertainties, including those described in the Risk Factors section of the 10-K filed with the SEC for year ended December 31, 2023.

Q: Last quarter, enrollment trends in the CRDF-004 trial were slower than anticipated. Has enrollment held steady or accelerated?

A: Enrollment is tracking well with guidance for initial data readout later this year, leveraging Pfizer Ignite as a partner and the lack of new drugs for RAS-mutated patients in first-line mCRC.

Q: On the pancreatic trial shifting to NALIRIFOX, why be aggressive given NALIRIFOX may not be broadly adopted?

A: NALIRIFOX has 3 of 4 chemo agents already combined with onvansertib in second line, and onvansertib is well tolerated with chemo, confident in adding value to this regimen.

Q: Comment on scientific validation of shifting pancreatic IST to NALIRIFOX and ovarian cancer ADC combinations?

A: Irinotecan synergy is a reason for NALIRIFOX shift, and preclinically exploring onvansertib with ADCs in several cancer areas.